vs

Side-by-side financial comparison of Axogen, Inc. (AXGN) and Hippo Holdings Inc. (HIPO). Click either name above to swap in a different company.

Hippo Holdings Inc. is the larger business by last-quarter revenue ($120.4M vs $61.5M, roughly 2.0× Axogen, Inc.). Hippo Holdings Inc. runs the higher net margin — 5.0% vs -31.9%, a 36.8% gap on every dollar of revenue. On growth, Axogen, Inc. posted the faster year-over-year revenue change (26.6% vs 18.2%). Hippo Holdings Inc. produced more free cash flow last quarter ($9.1M vs $-1.4M). Over the past eight quarters, Hippo Holdings Inc.'s revenue compounded faster (18.9% CAGR vs 13.3%).

Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is...

Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.

AXGN vs HIPO — Head-to-Head

Bigger by revenue
HIPO
HIPO
2.0× larger
HIPO
$120.4M
$61.5M
AXGN
Growing faster (revenue YoY)
AXGN
AXGN
+8.4% gap
AXGN
26.6%
18.2%
HIPO
Higher net margin
HIPO
HIPO
36.8% more per $
HIPO
5.0%
-31.9%
AXGN
More free cash flow
HIPO
HIPO
$10.5M more FCF
HIPO
$9.1M
$-1.4M
AXGN
Faster 2-yr revenue CAGR
HIPO
HIPO
Annualised
HIPO
18.9%
13.3%
AXGN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AXGN
AXGN
HIPO
HIPO
Revenue
$61.5M
$120.4M
Net Profit
$-19.6M
$6.0M
Gross Margin
75.2%
Operating Margin
20.2%
5.6%
Net Margin
-31.9%
5.0%
Revenue YoY
26.6%
18.2%
Net Profit YoY
-410.8%
-86.4%
EPS (diluted)
$-0.38
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXGN
AXGN
HIPO
HIPO
Q1 26
$61.5M
Q4 25
$59.9M
$120.4M
Q3 25
$60.1M
$120.6M
Q2 25
$56.7M
$117.3M
Q1 25
$48.6M
$110.3M
Q4 24
$49.4M
$101.9M
Q3 24
$48.6M
$95.5M
Q2 24
$47.9M
$89.6M
Net Profit
AXGN
AXGN
HIPO
HIPO
Q1 26
$-19.6M
Q4 25
$-13.2M
$6.0M
Q3 25
$708.0K
$98.1M
Q2 25
$579.0K
$1.3M
Q1 25
$-3.8M
$-47.7M
Q4 24
$450.0K
$44.2M
Q3 24
$-1.9M
$-8.5M
Q2 24
$-1.9M
$-40.5M
Gross Margin
AXGN
AXGN
HIPO
HIPO
Q1 26
75.2%
Q4 25
74.1%
Q3 25
76.6%
Q2 25
74.2%
Q1 25
71.9%
Q4 24
76.1%
Q3 24
74.9%
Q2 24
73.8%
Operating Margin
AXGN
AXGN
HIPO
HIPO
Q1 26
20.2%
Q4 25
-16.3%
5.6%
Q3 25
3.2%
81.3%
Q2 25
3.0%
3.4%
Q1 25
-3.4%
-41.3%
Q4 24
4.1%
46.3%
Q3 24
-0.6%
-5.4%
Q2 24
-0.9%
-40.7%
Net Margin
AXGN
AXGN
HIPO
HIPO
Q1 26
-31.9%
Q4 25
-22.0%
5.0%
Q3 25
1.2%
81.3%
Q2 25
1.0%
1.1%
Q1 25
-7.9%
-43.2%
Q4 24
0.9%
43.4%
Q3 24
-3.8%
-8.9%
Q2 24
-4.0%
-45.2%
EPS (diluted)
AXGN
AXGN
HIPO
HIPO
Q1 26
$-0.38
Q4 25
$-0.28
$0.31
Q3 25
$0.01
$3.77
Q2 25
$0.01
$0.05
Q1 25
$-0.08
$-1.91
Q4 24
$-0.00
$1.81
Q3 24
$-0.04
$-0.34
Q2 24
$-0.04
$-1.64

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXGN
AXGN
HIPO
HIPO
Cash + ST InvestmentsLiquidity on hand
$82.7M
$218.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$244.8M
$436.1M
Total Assets
$289.5M
$1.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXGN
AXGN
HIPO
HIPO
Q1 26
$82.7M
Q4 25
$41.5M
$218.3M
Q3 25
$35.8M
$247.7M
Q2 25
$29.9M
$198.9M
Q1 25
$22.1M
$140.9M
Q4 24
$33.5M
$197.6M
Q3 24
$24.5M
$191.2M
Q2 24
$21.1M
$175.9M
Total Debt
AXGN
AXGN
HIPO
HIPO
Q1 26
Q4 25
$48.4M
Q3 25
$48.2M
Q2 25
$47.9M
Q1 25
$47.7M
Q4 24
$47.5M
Q3 24
$47.3M
Q2 24
$47.0M
Stockholders' Equity
AXGN
AXGN
HIPO
HIPO
Q1 26
$244.8M
Q4 25
$128.8M
$436.1M
Q3 25
$120.8M
$421.5M
Q2 25
$112.3M
$332.5M
Q1 25
$105.4M
$322.8M
Q4 24
$103.9M
$362.1M
Q3 24
$99.4M
$326.4M
Q2 24
$95.7M
$322.6M
Total Assets
AXGN
AXGN
HIPO
HIPO
Q1 26
$289.5M
Q4 25
$221.7M
$1.9B
Q3 25
$216.4M
$1.9B
Q2 25
$205.5M
$1.7B
Q1 25
$196.2M
$1.5B
Q4 24
$203.7M
$1.5B
Q3 24
$192.0M
$1.5B
Q2 24
$188.9M
$1.5B
Debt / Equity
AXGN
AXGN
HIPO
HIPO
Q1 26
Q4 25
0.38×
Q3 25
0.40×
Q2 25
0.43×
Q1 25
0.45×
Q4 24
0.46×
Q3 24
0.48×
Q2 24
0.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXGN
AXGN
HIPO
HIPO
Operating Cash FlowLast quarter
$9.2M
Free Cash FlowOCF − Capex
$-1.4M
$9.1M
FCF MarginFCF / Revenue
-2.3%
7.6%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.53×
TTM Free Cash FlowTrailing 4 quarters
$9.1M
$14.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXGN
AXGN
HIPO
HIPO
Q1 26
Q4 25
$3.0M
$9.2M
Q3 25
$3.2M
$16.9M
Q2 25
$7.7M
$24.7M
Q1 25
$-13.2M
$-35.6M
Q4 24
$8.7M
$47.5M
Q3 24
$3.9M
$46.8M
Q2 24
$4.2M
$-10.6M
Free Cash Flow
AXGN
AXGN
HIPO
HIPO
Q1 26
$-1.4M
Q4 25
$1.8M
$9.1M
Q3 25
$1.7M
$16.8M
Q2 25
$7.0M
$24.6M
Q1 25
$-13.4M
$-35.7M
Q4 24
$8.1M
$47.2M
Q3 24
$3.3M
Q2 24
$3.3M
$-10.7M
FCF Margin
AXGN
AXGN
HIPO
HIPO
Q1 26
-2.3%
Q4 25
3.0%
7.6%
Q3 25
2.8%
13.9%
Q2 25
12.4%
21.0%
Q1 25
-27.7%
-32.4%
Q4 24
16.3%
46.3%
Q3 24
6.8%
Q2 24
6.8%
-11.9%
Capex Intensity
AXGN
AXGN
HIPO
HIPO
Q1 26
Q4 25
2.1%
0.1%
Q3 25
2.5%
0.1%
Q2 25
1.3%
0.1%
Q1 25
0.5%
0.1%
Q4 24
1.4%
0.3%
Q3 24
1.2%
0.0%
Q2 24
1.9%
0.1%
Cash Conversion
AXGN
AXGN
HIPO
HIPO
Q1 26
Q4 25
1.53×
Q3 25
4.55×
0.17×
Q2 25
13.35×
19.00×
Q1 25
Q4 24
19.41×
1.07×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons